论文部分内容阅读
目的近年来研究发现,LncRNA的异常表达与肿瘤的发生、发展、浸润、转移、复发及耐药等相关,但其具体机制尚未完全阐明。本研究探讨LncRNA RP11-164P12.4在非小细胞肺癌(non-small cell lung cancer,NSCLC)组织标本中的表达及临床意义。方法收集2011-01-01-2015-12-30四川省人民医院就诊临床资料完整的125例NSCLC组织、90例癌旁组织(距癌组织>2cm)及35例正常肺组织标本,通过QRT-PCR法检测LncRNA RP11-164P12.4的表达,分析其表达与临床预后的关系。结果 NSCLC组织LncRNA RP11-164P12.4的表达量为6.850±1.370,明显高于癌旁组织(1.225±0.750)和正常肺组织(1.092±0.69),差异有统计学意义,F=95.19,P<0.001。LncRNA RP11-164P12.4的表达与患者的年龄、性别、吸烟史、肿瘤大小、淋巴结转移及肿瘤分化无关,差异无统计学意义,均P>0.05;与疾病分期、远处转移、病理类型及生存状态明显相关,差异有统计学意义,均P<0.05。LncRNA RP11-164P12.4高表达水平与NSCLC中的腺癌类型相关,P<0.05;LncRNA RP11-164P12.4高表达组中腺癌的表达水平明显高于鳞癌及其他,P<0.001;LncRNA RP11-164P12.4低表达组患者总生存时间(overall survival,OS)为(44.89±3.64)个月,较高表达组(21.83±3.74)个月明显延长,差异有统计学意义,χ2=49.210,P<0.001。LncRNA RP11-164P12.4高表达组患者无进展生存时间(progression-free-survival,PFS)为(13.55±2.84)个月,较低表达组(24.00±2.75)个月缩短,差异有统计学意义,χ~2=50.18,P<0.001;Cox多因素回归模型分析提示,LncRNA RP11-164P12.4的表达、淋巴转移远处转移和临床分期是NSCLC独立的预后因素,P<0.05。结论 LncRNA RP11-164P12.4参与调节NSCLC的发生发展,可作为潜在的NSCLC诊断和预后评估的分子标志物。
In recent years, it has been found that the abnormal expression of LncRNA correlates with the occurrence, development, invasion, metastasis, recurrence and drug resistance of tumor, but its exact mechanism has not been fully elucidated. This study was to investigate the expression and clinical significance of LncRNA RP11-164P12.4 in non-small cell lung cancer (NSCLC) tissue samples. Methods Totally 125 cases of NSCLC, 90 cases of paracancerous tissues (> 2 cm away from cancer) and 35 normal lung tissues were collected from 2011-01-01-2015-12-30 in Sichuan People’s Hospital. PCR method was used to detect the expression of LncRNA RP11-164P12.4 and its relationship with clinical prognosis was analyzed. Results The expression level of LncRNA RP11-164P12.4 in NSCLC was 6.850 ± 1.370, which was significantly higher than that in paracancerous tissues (1.225 ± 0.750) and normal lung tissues (1.092 ± 0.69), the difference was statistically significant (F = 95.19, P < 0.001. The expression of LncRNA RP11-164P12.4 was not related with the age, sex, smoking history, tumor size, lymph node metastasis and tumor differentiation, and there was no significant difference (all P> 0.05). The correlation between the expression of LncRNA RP11-164P12.4 and the pathological stage, distant metastasis, Survival status was significantly related, the difference was statistically significant, P <0.05. The expression level of LncRNA RP11-164P12.4 was correlated with the type of adenocarcinoma in NSCLC (P <0.05). The expression of LncRNA in RP11-164P12.4 overexpression group was significantly higher than that in squamous cell carcinoma and others (P <0.001) The overall survival (OS) of patients with low expression of RP11-164P12.4 was (44.89 ± 3.64) months, while that of the patients with high expression of RP11-164P12.4 (21.83 ± 3.74) was significantly longer, with significant difference (χ2 = 49.210 , P <0.001. The progression-free survival (PFS) of LncRNA RP11-164P12.4 overexpression group was (13.55 ± 2.84) months, and that of the lower expression group (24.00 ± 2.75) months was shorter, the difference was statistically significant , χ ~ 2 = 50.18, P <0.001. Cox regression analysis indicated that the expression of RP11-164P12.4, distant metastasis and clinical stage of LncRNA were independent prognostic factors of NSCLC, P <0.05. Conclusions LncRNA RP11-164P12.4 is involved in the regulation of the development of NSCLC and may be used as a potential molecular marker for the diagnosis and prognosis of NSCLC.